Boqing Wang

机构：Xinjiang Medical University, First Affiliated Hospital of Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University

发表论文 45 篇 · 总被引 1020 次 · h-index 12

代表论文

• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 514)
• MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma (2019 · EBioMedicine · 被引 72)
• Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance (2021 · British Journal of Cancer · 被引 44)
• Lysyl oxidase assists tumor‑initiating cells to enhance angiogenesis in hepatocellular carcinoma (2019 · International Journal of Oncology · 被引 33)
• GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma (2024 · Pharmacological Research · 被引 20)
• MicroRNA-143 inhibits tumorigenesis in hepatocellular carcinoma by downregulating GATA6 (2017 · Experimental and Therapeutic Medicine · 被引 19)